Humana Inc. (NYSE:HUM) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its position in shares of Humana Inc. (NYSE:HUM) by 19.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 724,404 shares of the insurance provider’s stock after selling 179,044 shares during the period. Janus Henderson Group PLC owned about 0.60% of Humana worth $183,733,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in HUM. Principal Financial Group Inc. raised its position in shares of Humana by 2.4% during the 3rd quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider’s stock valued at $54,047,000 after acquiring an additional 3,961 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Humana by 6.6% during the 4th quarter. Nordea Investment Management AB now owns 9,679 shares of the insurance provider’s stock valued at $2,487,000 after acquiring an additional 602 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Humana by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,848 shares of the insurance provider’s stock valued at $2,245,000 after acquiring an additional 138 shares in the last quarter. Czech National Bank increased its position in Humana by 6.4% in the fourth quarter. Czech National Bank now owns 26,108 shares of the insurance provider’s stock worth $6,624,000 after buying an additional 1,581 shares during the period. Finally, Fiduciary Alliance LLC acquired a new stake in Humana in the fourth quarter worth $1,375,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

NYSE:HUM opened at $249.67 on Monday. The business’s 50-day moving average price is $265.21 and its 200 day moving average price is $270.47. The firm has a market cap of $30.13 billion, a P/E ratio of 25.09, a PEG ratio of 2.05 and a beta of 0.49. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. During the same quarter last year, the company posted $7.23 EPS. Humana’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana’s dividend payout ratio (DPR) is 25.04%.

Analysts Set New Price Targets

Several brokerages have weighed in on HUM. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a research report on Thursday, May 1st. Robert W. Baird increased their target price on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 15th. JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, Guggenheim began coverage on Humana in a research report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price on the stock. Seventeen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $287.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.